Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications
-
Published:2023-07-14
Issue:
Volume:31
Page:
-
ISSN:0929-8673
-
Container-title:Current Medicinal Chemistry
-
language:en
-
Short-container-title:CMC
Author:
Xiao Qicai1,
Gao Liqian1ORCID,
Chen Peng1,
Lou Liang1,
Sharma Bigyan1,
Li Mengchu1,
Xie Chengliang1,
Yang Fen1,
Wu Yihang1
Affiliation:
1. School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, P. R. China
Abstract
Abstract:
Metabolic reprogramming of cells, from the normal mode of glucose metabolism named glycolysis, is a pivotal characteristic of impending cancerous cells. Pyruvate kinase M2 (PKM2), an important enzyme that catalyzes the final rate-limiting stage during glycolysis, is highly expressed in numerous types of tumors and aids in development of favorable conditions for the survival of tumor cells. Increasing evidence has suggested that PKM2 is one of promising targets for innovative drug discovery, especially for the developments of antitumor therapeutics. Herein, we systematically summarize the recent advancement on PKM2 modulators including inhibitors and activators in cancer applications. We also discussed the classifications of pyruvate kinases in mammals and the biological functions of PKM2 in this review. We do hope that this review would provide a comprehensive understanding of the current research on PKM2 modulators, which may benefit the development of more potent PKM2-related drug candidates to treat PKM2-associated diseases including cancers in future.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry